Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 96.35 CHF -0.6% Market Closed
Market Cap: 190.3B CHF
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NOVN stock under the Base Case scenario is 100.52 CHF. Compared to the current market price of 96.35 CHF, Novartis AG is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVN Relative Value
Base Case
100.52 CHF
Undervaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
11
vs Industry
29
Median 3Y
3.6
Median 5Y
3.3
Industry
2.4
Forward
4.1
More Details
18.5
P/E
P/E
Price to Earnings
18.5
vs History
41
vs Industry
33
Median 3Y
13.5
Median 5Y
16.1
Industry
20.2
Forward
13.5
More Details
12.5
P/OCF
P/OCF
Price to OCF
12.5
vs History
26
vs Industry
29
Median 3Y
12.4
Median 5Y
12.1
Industry
15.1
More Details
12.6
P/FCFE
P/FCFE
Price to FCFE
12.6
vs History
71
vs Industry
22
Median 3Y
22.1
Median 5Y
19.7
Industry
22.3
More Details
5.3
P/B
P/B
Price to Book Value
5.3
vs History
4
vs Industry
14
Median 3Y
3.8
Median 5Y
3.1
Industry
2
More Details
4.5
EV/S
EV/S
Enterprise Value to Sales
4.5
vs History
11
vs Industry
26
Median 3Y
3.7
Median 5Y
3.6
Industry
2.5
Forward
4.3
More Details
6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6
vs History
14
vs Industry
35
Median 3Y
4.9
Median 5Y
5
Industry
4.9
More Details
11.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.2
vs History
6
vs Industry
33
Median 3Y
9.6
Median 5Y
9.7
Industry
12.3
Forward
10.7
More Details
14.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.3
vs History
53
vs Industry
28
Median 3Y
13.8
Median 5Y
14.6
Industry
15.3
Forward
12.2
More Details
13.3
EV/OCF
EV/OCF
Enterprise Value to OCF
13.3
vs History
34
vs Industry
28
Median 3Y
12.9
Median 5Y
12.8
Industry
13.6
More Details
16.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.9
vs History
28
vs Industry
21
Median 3Y
15.7
Median 5Y
15.5
Industry
17.5
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
4
vs Industry
29
Median 3Y
2.1
Median 5Y
1.7
Industry
1.7
More Details

Multiples Across Competitors

NOVN Competitors Multiples
Novartis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Novartis AG
SIX:NOVN
195.1B CHF 4.3 18.5 11.2 14.3
US
Eli Lilly and Co
NYSE:LLY
770.8B USD 17.1 72.8 42.3 46.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
391.9B USD 4.4 27.9 13 17.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK 8.1 23.3 15.3 17.4
CH
Roche Holding AG
SIX:ROG
243.8B CHF 4.2 21.2 11.8 14
UK
AstraZeneca PLC
LSE:AZN
186B GBP 4.4 34.2 127.5 194.8
US
Merck & Co Inc
NYSE:MRK
239.5B USD 3.7 14 9.4 11.1
IE
Endo International PLC
LSE:0Y5F
158.2B USD 68.2 -54.1 253.2 634.9
US
Pfizer Inc
NYSE:PFE
145.7B USD 2.3 18.1 8.6 12.3
FR
Sanofi SA
PAR:SAN
132.5B EUR 3 23.1 10 14.6
P/E Multiple
Earnings Growth PEG
CH
Novartis AG
SIX:NOVN
Average P/E: 28.1
18.5
16%
1.2
US
Eli Lilly and Co
NYSE:LLY
72.8
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
19%
1.2
CH
Roche Holding AG
SIX:ROG
21.2
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
34.2
36%
0.9
US
Merck & Co Inc
NYSE:MRK
14
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -54.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.1
29%
0.6
FR
Sanofi SA
PAR:SAN
23.1
29%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Novartis AG
SIX:NOVN
Average EV/EBITDA: 395.3
11.2
4%
2.8
US
Eli Lilly and Co
NYSE:LLY
42.3
29%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
11%
1.4
CH
Roche Holding AG
SIX:ROG
11.8
7%
1.7
UK
AstraZeneca PLC
LSE:AZN
127.5
8%
15.9
US
Merck & Co Inc
NYSE:MRK
9.4
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
253.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.6
2%
4.3
FR
Sanofi SA
PAR:SAN
10
7%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Novartis AG
SIX:NOVN
Average EV/EBIT: 1 698.1
14.3
9%
1.6
US
Eli Lilly and Co
NYSE:LLY
46.7
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.1
11%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
16%
1.1
CH
Roche Holding AG
SIX:ROG
14
9%
1.6
UK
AstraZeneca PLC
LSE:AZN
194.8
19%
10.3
US
Merck & Co Inc
NYSE:MRK
11.1
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
634.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.3
10%
1.2
FR
Sanofi SA
PAR:SAN
14.6
14%
1

See Also

Summary
NOVN intrinsic value, competitors valuation, and company profile.
DCF Valuation
NOVN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NOVN stock valuation using valuation multiples.
Wall Street Estimates
NOVN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NOVN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 238,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.